Published in Cell Cycle on March 26, 2009
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Obesity and cancer. Oncologist (2010) 3.01
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol (2010) 2.46
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A (2012) 2.11
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
Diabetes and pancreatic cancer. Mol Carcinog (2012) 1.71
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep (2012) 1.66
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55
Metformin for aging and cancer prevention. Aging (Albany NY) (2010) 1.51
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45
Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res (2011) 1.43
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun (2012) 1.41
The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol (2013) 1.41
LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene (2009) 1.34
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.33
Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist (2013) 1.32
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res (2010) 1.25
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat (2009) 1.23
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY) (2010) 1.22
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 1.21
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One (2011) 1.19
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One (2014) 1.10
Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer (2011) 1.10
Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One (2013) 1.09
Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem (2012) 1.08
Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal (2011) 1.04
Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol (2013) 1.04
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle (2013) 1.03
AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PLoS One (2013) 1.02
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) (2015) 1.02
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int (2014) 1.00
Synergistic anti-cancer effect of phenformin and oxamate. PLoS One (2014) 0.99
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle (2013) 0.99
Metabolism and breast cancer risk: frontiers in research and practice. J Acad Nutr Diet (2012) 0.96
Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep (2013) 0.96
Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin Transl Med (2014) 0.93
Clinical benefits of metformin in gynecologic oncology. Oncol Lett (2015) 0.91
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One (2014) 0.91
Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res Treat (2014) 0.90
Anti-angiogenic Effects of Metformin, an AMPK Activator, on Human Umbilical Vein Endothelial Cells and on Granulation Tissue in Rat. Iran J Basic Med Sci (2012) 0.90
Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One (2012) 0.90
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer (2014) 0.89
Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med (2013) 0.89
Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. Oncol Lett (2016) 0.89
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. Diabetes (2015) 0.89
Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis. Oncologist (2015) 0.89
Metformin effects revisited. Diabetes Res Clin Pract (2011) 0.88
The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches. Front Endocrinol (Lausanne) (2014) 0.87
The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes. Diabetes Metab J (2013) 0.86
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res (2015) 0.86
Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions. PLoS One (2015) 0.85
The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int (2015) 0.85
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget (2014) 0.84
Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat. Cancer Prev Res (Phila) (2015) 0.84
Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease. Curr Mol Med (2010) 0.84
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med (2014) 0.84
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol (2012) 0.84
Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells. J Cancer (2011) 0.84
Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncol Lett (2012) 0.83
Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol Lett (2014) 0.83
A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol (2016) 0.83
Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget (2016) 0.82
Effect of Metformin on Viability, Morphology, and Ultrastructure of Mouse Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells and Balb/3T3 Embryonic Fibroblast Cell Line. Biomed Res Int (2015) 0.82
Metformin and sex: Why suppression of aging may be harmful to young male mice. Aging (Albany NY) (2010) 0.82
Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. Cell Cycle (2016) 0.82
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol (2013) 0.81
Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. BMC Cancer (2012) 0.81
The influence of metformin in the etiology of selected cancers. Contemp Oncol (Pozn) (2012) 0.81
Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget (2016) 0.81
Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget (2016) 0.80
Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget (2016) 0.80
Pharmacologic regulation of AMPK in breast cancer affects cytoskeletal properties involved with microtentacle formation and re-attachment. Oncotarget (2015) 0.80
Metformin in breast cancer - an evolving mystery. Breast Cancer Res (2015) 0.79
Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis (2015) 0.79
Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. Oncologist (2016) 0.79
Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care (2015) 0.79
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One (2015) 0.79
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Curr Pharmacol Rep (2015) 0.78
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. Cancer Sci (2016) 0.78
Metformin for endometrial hyperplasia: a Cochrane protocol. BMJ Open (2016) 0.78
In Vitro and In Vivo Effects of Metformin on Osteopontin Expression in Mice Adipose-Derived Multipotent Stromal Cells and Adipose Tissue. J Diabetes Res (2015) 0.77
Functional effects of a pathogenic mutation in Cereblon (CRBN) on the regulation of protein synthesis via the AMPK-mTOR cascade. J Biol Chem (2014) 0.77
Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo. Oxid Med Cell Longev (2016) 0.76
Metabolic syndrome in breast cancer. Gland Surg (2013) 0.76
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol (2005) 2.95
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
Light regulates COP1-mediated degradation of HFR1, a transcription factor essential for light signaling in Arabidopsis. Plant Cell (2005) 2.31
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res (2010) 1.94
Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res (2006) 1.78
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer (2007) 1.50
Anticancer activity of the antibiotic clioquinol. Cancer Res (2005) 1.47
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle (2012) 1.41
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol (2003) 1.33
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem (2010) 1.23
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res (2008) 1.23
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle (2011) 1.16
Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. Cancer Res (2005) 1.14
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol (2009) 1.12
Repression of light signaling by Arabidopsis SPA1 involves post-translational regulation of HFR1 protein accumulation. Plant J (2005) 1.10
Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol Cancer Ther (2004) 1.08
HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett (2010) 1.06
HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res (2009) 1.05
Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res (2005) 1.05
Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res (2003) 1.03
Metal ionophores - an emerging class of anticancer drugs. IUBMB Life (2009) 1.02
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res (2005) 1.02
c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol (2002) 1.02
Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) (2013) 1.02
Clioquinol targets zinc to lysosomes in human cancer cells. Biochem J (2009) 1.01
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol (2009) 0.98
Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol (2002) 0.98
Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci U S A (2002) 0.98
Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-alpha induced apoptosis. Apoptosis (2006) 0.95
Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett (2008) 0.94
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res (2011) 0.94
Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer. Mol Carcinog (2011) 0.94
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer (2013) 0.93
Activation of peroxisome proliferator-activated receptor α (PPARα) suppresses hypoxia-inducible factor-1α (HIF-1α) signaling in cancer cells. J Biol Chem (2012) 0.93
Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res (2012) 0.93
Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells. Oncol Rep (2011) 0.92
Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett (2011) 0.92
Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family. Proc Natl Acad Sci U S A (2003) 0.92
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett (2011) 0.91
Gypenoside attenuates white matter lesions induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav (2011) 0.91
Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther (2006) 0.90
Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. Int J Oncol (2005) 0.89
Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis (2003) 0.89
Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res (2009) 0.88
The expression profile of FRAT1 in human gliomas. Brain Res (2010) 0.88
Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. Breast Cancer Res (2014) 0.88
Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res (2013) 0.87
FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas. Med Oncol (2009) 0.87
Glaucocalyxin A, a negative Akt regulator, specifically induces apoptosis in human brain glioblastoma U87MG cells. Acta Biochim Biophys Sin (Shanghai) (2013) 0.87
Prognostic significance of kappaB-Ras1 expression in gliomas. Med Oncol (2011) 0.87
A review of current management of brain metastases. Ann Surg Oncol (2011) 0.87
N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Lett (2010) 0.87
Caspase expression profile and functional activity in a panel of breast cancer cell lines. Oncol Rep (2007) 0.87
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Lett (2013) 0.86
Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity. Mol Cancer Ther (2007) 0.86
Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion. PLoS One (2013) 0.86
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res (2013) 0.86
Zinc protoporphyrin suppresses cancer cell viability through a heme oxygenase-1-independent mechanism: the involvement of the Wnt/β-catenin signaling pathway. Biochem Pharmacol (2013) 0.86
Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. Comp Med (2004) 0.85
Fabrication and characterization of three-dimensional silicon tapers. Opt Express (2003) 0.84
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood (2005) 0.84